Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascle...
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
Ascletis Received IND Approval for its NASH Drug
HANGZHOU, China and SHAOXING, China, Aug. 28, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that toget...
Ascletis Opens Clinical Development Shanghai Center
HANGZHOU and SHAOXING, China, Aug. 12, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of it...
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
HANGZHOU and SHAOXING, China, Aug. 5, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that it received I...
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
SAN MATEO, Calif. and HANGZHOU and SHAOXING, China, May 1, 2019 /PRNewswire/ -- 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK)announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inh...
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
HANGZHOU and SHAOXING, China, April 15, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that according to the official...
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
HANGZHOU, China and SHAOXING, China, March 1, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr. Z...
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
HANGZHOU and SHAOXING, China and SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for...
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
HANGZHOU, China and SHAOXING, China and SUZHOU, China, Jan. 14, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) and Suzhou Alphamab Co., Ltd. (Alphamab) jointly announce today that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing ...
Ascletis' IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA
HANGZHOU and SHAOXING, China, Jan. 3, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that the investigational new drug applicat...
Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu
HANGZHOU, China and SHAOXING, China, Jan. 2, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ganovo® (Danoprevir) has been ...
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
SHANGHAI, HANGZHOU and SHAOXING, China, Nov. 20, 2018 /PRNewswire/ -- Shanghai Roche Pharmaceuticals Ltd. (Roche) and Ascletis BioScience Co., Ltd. (Ascletis, listed parent company stock code 1672.HK) jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnershi...
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
HANGZHOU and SHAOXING, China, Nov. 11, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) , a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Lindi Tan joins Ascletis as Chie...
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD
HANGZHOU, China and SHAOXING, China, Nov. 6, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company developing innovative drugs to address unmet needs in anti-viral, cancer and fatty liver disease therapeutic areas, announces today that a phase II / III clin...
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
HANGZHOU and SHAOXING, China, Oct. 18, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announces today the New Drug Application (NDA) of Ravidasvir is on the List of Proposed Priority Review, according to the public notification by the China Food and Drug Administration (CFDA) onOct 17th, 201...
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients
HANGZHOU, China and SHAOXING, China, Oct. 15, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today Ganovo® (Danoprevir) is the only direct-acting anti-viral agent (DAA) eligible for Shaoxing government funding subsidy, according toShaoxing's Action Plan to Accelerate Prevention and...
Ganovo Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program
HANGZHOU and SHAOXING, China, Sept. 26, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today that Ganovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ("Pilot Program") for outpatients with hepatitis C. The...
